There is much evidence for identifying and altering certain risk factors, such as hypertension, diabetes, raised cholesterol levels, smoking, obesity, hormone changes and exercise to reduce the incidence of cardiovascular disease; certain drugs have also been shown to be of benefit. Although the elderly population is most likely to suffer cardiovascular disease, very little of the trial evidence has looked at this patient group. It is important that the interventions we recommend for young patients have a comparable risk/benefit profile in the elderly so that we can offer them the most appropriate treatment.
Coronary Heart Disease Statistics.British Heart Foundation Statistics Database1997, 1998.
2.
Coronary Heart Disease Statistics.Economic supplement. British Heart Foundation Statistics Database1997, 1998.
3.
KannelWB.Cardiovascular risk factors in the elderly. Coron Artery Dis1997; 8:565–575.
4.
StarrJMBulpittCJ.Hypertension. In EbrahimS (editor): Epidemiology in old age. London: BMJ Publishing Group; 1996.
5.
RamseyLEWilliamsBJohnstonGDMacGregorGAPostonLPotterJFGuidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens1999; 13:569–592.
6.
AmeryABirkenhagerWBrixhoPBulpittCClementDDeruyttereMMortality and morbidity results from the European Working Party in High Blood Pressure in the Elderly trial. Lancet1985; i:1349–1354.
7.
SHEEP Co-operative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1991; 265:3255–3264.
8.
DahlofBLindholmLHHanssonLScherstenBEkbomTWesterPO.Morbidity and mortality in the Swedish Trial of Old Patients with Hypertension (STOP-Hypertension). Lancet1991; 338:1281–1285.
9.
MRC Working Party.Medical Research Council trial of treatment of hypertension in older adults. BMJ1992; 304:405–412.
10.
StaessenJAFagardRThijSLLetisHArabidreGGBirkenhagerWHFor the Systolic Hypertension Europe (Syst-Eur) Trial investigators. Morbidity and mortality in the placebo controlled European trial on isolated systolic hypertension in the elderly. Lancet1997; 360:757–764.
11.
Australian Therapeutic Trial management Committee.The Australian therapeutic trial in mild hypertension. Lancet1980; i:1261–1267.
12.
CoopeJWarrenderTS.Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986; 293:1145–1151.
13.
BulpittCJFletcherAEAmeryACoopeJEvansJGLightowerSThe Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology, and comparison with previous trials. Drugs Aging1994; 5:171–183.
14.
CappuccioFPMarkanduNDCarneyCSagnellaGAMacGregorGA.Double blind randomised trial of modest salt restriction in older people. Lancet1997; 350:850–854.
15.
MacGregorGASmithSJMarkanduNDBanksRASagnellaGA.Moderate potassium supplementation in essential hypertension. Lancet1982; 2:567–570.
16.
DyerARElliottP.The INTERSALT Study: Relations of BMI to blood pressure. J Hum Hypertens1989; 3:299–308.
17.
KlatskyALFriedmanGDSpieglaubABGerardMJ.Alcohol consumption and blood pressure. Kaiser Permanente Multiphasic Health Examination Data. N Eng J Med1977; 296:1194–2000.
18.
PotterJFBeeversDG.Pressor effect of alcohol in hypertension. Lancet1984; 1:119–122.
19.
FagardRH.Physical fitness and blood pressure. J Hypertens1993; 11:547–552.
20.
MensinkGBZieseTKokFJ.Benefits of leisure-time physical activity on the cardiovascular risk profile at older age. Int J Epidemiol1999; 28:659–666.
21.
LeverAFRamsayLE.Treatment of hypertension in the elderly. J Hypertens1995; 13:571–579.
Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1384–1389.
24.
The Standing Medical Advisory Committee.The Use of StatinsLondon: The Department of Health; 1997.
25.
EttingerWHWahlPWKullerLHBushTLTracyRPManolioTALipoprotein lipids in older people. Circulation1992; 86:858–869.
26.
KennedyRDAndrewsGRCairdFI.Ischaemic heart disease in the elderly. Br Heart J1977; 39:1121–1127.
27.
Long term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339:1349–1357.
28.
MiettinenTAPyorallaKOlssonAGMusliverTACookTJFaergemenOCholesterol lowering therapy in women and elderly patients with myocardial infarction and angina. Circulation1997; 96:4211–4218.
29.
DownsJRClearfieldMWeisSWhitneyEShapirolDRBeerzPAPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA1998; 279:1615–1622.
30.
ClaudioBVeronesiMPrandinMGDormiAAmbrosioniE.Statins and blood pressure regulation. Curr Hypertens Rep2001; 3:281–288.
31.
SinclairAJ.Diabetes in the elderly. A perspective from the United Kingdom. Clin Geriat Med1999; 15:225–237.
32.
TurnerRCMillnsHNeilHAWStrattonIMManleySEMatthewsDRRisk factors for coronary artery disease in non-insulin dependant diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ; 316: 823–828.
33.
UK Prospective Diabetes Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317:703–713.
34.
The Diabetes Control and Complications Trial (DCCT) Research Group.The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin dependent diabetes mellitus. N Eng J Med1993; 239:77–86.
35.
SinclairAJRobertIECroxsonSCM.Mortality in older people with diabetes mellitus. Diabet Med1997; 14:639–647.
36.
ParishSCollinsRPetoRYougmanLBartonJJayneKCigarette smoking, tar yields and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. BMJ1995; 311:471–477.
37.
BurnsDM.Cigarette smoking among the elderly: Disease consequences and benefits of cessation. Am J Health Promot2000; 14 (6):357–361.
38.
WoodDde BackerGFaergemanOGrahamIManciaGPyoralaK.Prevention of coronary heart disease in clinical practice. Summary of Recommendations of the Second Joint Task Force of the European and other societies on coronary prevention. Blood Press1998; 5–6:262–269.
39.
MansonJEWillettWCStampferMJColditzGAHunterDJHankinsonSEBody weight and mortality among women. N Engl J Med1995; 333:677–685.
40.
De LorgerilMSalenPMartinJLMonjaudIDelayeJMamelleN.Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction in final report of the Lyon Diet Heart Study. Circulation1999; 99:779–785.
41.
RajkumarCCameronJChristophidisN.Reduction in systolic arterial compliance is associated with left ventricular hypertrophy and diastolic dysfunction in older people. J Am Geriat Soc1997; 45:803–808.
42.
GradyDRubinSMPetittiDBFoxCSBlackDEttingerBHormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med1992; 117:1016–1037.
43.
O'ConnerGTBuringJEYusufSGoldhaberSZOlmsteadEMPaffenbargerRS.An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation1989; 80:234–244.
44.
RajkumarCSchiffR.HRT in the Over 65s. In: Yearbook of obstetrics and gynaecology1999. London: Royal College of Obstetricians and Gynaecologists; 1999. Chapter 14; pp. 129–135.
45.
WrenBG.Mega-trials of hormone replacement therapy. Drugs and Aging1998; 12:343–348.
46.
WannametheeSGShaperAGWalkerM.Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet1998; 351:1603–1608.
47.
WoodwardMLoweGDRumleyATunstall-PedoeH.Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J1998; 19:55–62.
48.
LeeAJLoweGDWoodwardMTunstall-PedoeH.Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: The Scottish Heart Health Study. Br Heart J1993; 69:338–342.
49.
HoogwerfBJYoungJB.The HOPE Study. Ramipril lowered cardiovascular risk but vitamin E did not. Cleve Clin J Med2000; 67:287–293.
50.
Anonymous.Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet1999; 354:447–455.
51.
TomonariOKitamuraAMoriyamaYImanoHSataSTeraoAPlasma level of homocysteine is correlated to extra-cranial carotid-artery atherosclerosis in non-hypertensive Japanese. J Cariovasc Risk1999; 6:371–377.
52.
Rich-EdwardsJWStampferMJMansonJERosnerBHankinsonSEColditzGABirth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ1997; 315:396–400.
53.
HanssonLZanchettiACarruthersSGDahlofBElmfieldtDJuliusSEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998; 351:1755–1762.
54.
Antiplatelet Trialists Collaboration.Collaborative overview of randomised trials of anti-platelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ1994; 308:81.
55.
BaigentCCollinsRApplebyPParishSSleightPPetoR.ISIS-2 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 Collaborative Group. BMJ1998; 316:1337–1343.
56.
CAPRIE Steering Committee.A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet1996; 348:1329–1339.
57.
West of Scotland Coronary Prevention Study Group.Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998; 97:1440–1445.
58.
LansbergPJMitchelYBShapiroDKasteleinJJAltmanRJerumsGLong-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Atherosclerosis1995; 116:153–162.
59.
YusufSPetoRLewisJCollinsRSleightP.Beta blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis1985; 27:335–371.
60.
FlatherMYusufSKoberLPfefferMHallAMurrayGLongterm ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients. Lancet2000; 355:1575–1581.
61.
Blood Pressure Lowering Treatment Trialists' Collaboration.Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet2000; 356:1955–1964.
